N/A N=10 Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder
Body Dysmorphic Disorders
Primary: Treatment Completion Rates — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=214 Study of Secukinumab With 2 mL Pre-filled Syringes
Psoriasis
Primary: Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment — 64; 1 participants — p=< 0.0001
Phase 3 N=60 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Extraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 88; 83; 28 Probability
Phase 2 N=48 Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Squamous Cell Cancer · Head and Neck Cancer
Primary: Phase II Recommended Dose for the Combination of Temsirolimus + Weekly Paclitaxel + Carboplatin. — 25 mg
Phase 3 N=2,254 Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 0.99; 1.21; 1.09; 1.17 Exacerbations per year — p=0.0638
Phase 2 N=199 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Acute Biphenotypic Leukemia · de Novo Myelodysplastic Syndrome · Previously Treated Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities of Mitoxantrone (Phase I, Dose Level 4) — 1; 2 Participants
Phase 3 N=849 Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
Osteoarthritis, Hip · Osteoarthritis, Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24 — -2.24; -2.70; -2.85 units on a scale — p=0.0088
Phase 2 N=25 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Granulomatosis With Polyangiitis
Primary: Percentage of Participants With Adverse Events (AEs), Including Serious AEs — 100; 100; 28; 48 percentage of participants
Phase 1 N=28 A Study of LY2216684 in Healthy Participants
Major Depressive Disorder
Primary: Change From Baseline to 10 Hours in Power of Attention Composite Score — 67.82; 52.77; 20.6; 6.78 minutes
Phase 4 N=230 RNS® System LTT Study
Epilepsy
Primary: Number of Participants With Serious Adverse Events (SAE) — 177 Participants
Phase 2 N=15 Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Maximum Observed Concentration (Cmax) of GSK3196165 — 699.92; 1444.88; 3924.10 Nanogram per milliliter (ng/mL)
Phase 3 N=647 Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: ACR-20 - 20% Improvement According to American College of Rheumatology Criteria — 232; 233 Participants
Phase 2 N=378 Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients
Chronic Hepatitis B
Primary: Percentage of Participants With HBeAg Seroconversion at Week 48 — 21; 23 Participants
Phase 3 N=134 Combined Behavioral and Analgesic Trial for Fibromyalgia
Fibromyalgia
Primary: Number of Participants With a 30% Improvement in Pain or 20% Improvement in Function — 24; 13; 21; 15 Participants
N/A N=657 Long Term Safety Protocol for the AcrySof CACHET Phakic Lens
Myopia
Primary: Central Endothelial Cell Density (All Eyes) — 2654.0; 2639.0; 2633.0; 2551.0 cells/mm^2